Patents by Inventor Fabio Tucci
Fabio Tucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124423Abstract: Pyrimidine and Pyridine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic metabolic and certain neurological disorders.Type: ApplicationFiled: December 6, 2023Publication date: April 18, 2024Applicant: Epigen Biosciences, Inc.Inventors: Graham Beaton, Fabio Tucci, Satheesh Ravula, Suk Joong Lee, Chandravadan Shah
-
Patent number: 11866421Abstract: Pyrimidine and Pyridine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic metabolic and certain neurological disorders.Type: GrantFiled: May 31, 2021Date of Patent: January 9, 2024Assignee: Epigen Biosciences, INC.Inventors: Graham Beaton, Fabio Tucci, Satheesh Ravula, Suk Joong Lee, Chandravadan Shah
-
Publication number: 20230346701Abstract: Described herein is a chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug, as described herein.Type: ApplicationFiled: June 19, 2023Publication date: November 2, 2023Applicants: BRUIN BIOSCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: James NA, David IMAGAWA, Fabio TUCCI, Graham BEATON, Satheesh RAVULA
-
Patent number: 11712418Abstract: A chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug.Type: GrantFiled: May 25, 2018Date of Patent: August 1, 2023Assignees: BRUIN BIOSCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: James Na, David Imagawa, Fabio Tucci, Graham Beaton, Satheesh Ravula
-
Publication number: 20220396564Abstract: Pyrimidine and Pyridine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic metabolic and certain neurological disorders.Type: ApplicationFiled: May 31, 2021Publication date: December 15, 2022Applicant: Epigen Biosciences, Inc.Inventors: Graham Beaton, Fabio Tucci, Satheesh Ravula, Suk Joong Lee, Chandravadan Shah
-
Publication number: 20210169801Abstract: A chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug.Type: ApplicationFiled: May 25, 2018Publication date: June 10, 2021Applicants: BRUIN BIOSCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: James NA, David IMAGAWA, Fabio TUCCI, Graham BEATON, Satheesh RAVULA
-
Patent number: 10227333Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: GrantFiled: February 10, 2016Date of Patent: March 12, 2019Assignee: CURTANA PHARMACEUTICALS, INC.Inventors: Graham Beaton, Fabio Tucci, Satheesh B. Ravula, Hua-Yu Wang
-
Publication number: 20160237069Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: ApplicationFiled: February 10, 2016Publication date: August 18, 2016Inventors: Graham BEATON, Fabio TUCCI, Satheesh B. RAVULA, Hua-Yu WANG
-
Publication number: 20070208049Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, Q, R1, R2, R3a, R3b, R4, R5, R6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: ApplicationFiled: September 11, 2006Publication date: September 6, 2007Applicant: Neurocrine Biosciences, Inc.Inventors: Yun-Fei Zhu, Chen Chen, Fabio Tucci, Zhiqiang Guo, Timothy Gross, Martin Rowbottom, R. Struthers
-
Publication number: 20070191403Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: ApplicationFiled: January 25, 2007Publication date: August 16, 2007Applicant: NEUROCRINE BIOSCIENCES, INC.Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley Dwight, Charles Huang, Fabio Tucci
-
Publication number: 20060122202Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: ApplicationFiled: October 14, 2005Publication date: June 8, 2006Applicant: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley Dwight, Charles Huang, Fabio Tucci
-
Publication number: 20060019996Abstract: GnPRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, R1, R2, R3a, R3b, R4, R5, R6 R7 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: ApplicationFiled: June 24, 2005Publication date: January 26, 2006Applicant: Neurocrine Biosciences, Inc.Inventors: Fabio Tucci, Patrick Connors, Yun-Fei Zhu, Chen Chen
-
Publication number: 20050234082Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, Q, R1, R2, R3a, R3b, R4, R5, R6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: ApplicationFiled: December 17, 2004Publication date: October 20, 2005Applicant: Neurocrine Biosciences, Inc.Inventors: Yun-Fei Zhu, Chen Chen, Fabio Tucci, Zhiqiang Guo, Timothy Gross, Martin Rowbottom, R. Struthers
-
Patent number: 6939883Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, R1, R2, R3a, R3b, R4, R5, R6, R7 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: August 2, 2002Date of Patent: September 6, 2005Assignee: Neurocrine Biosciences, Inc.Inventors: Fabio Tucci, Patrick J. Connors, Yun-Fei Zhu, Chen Chen
-
Publication number: 20050192286Abstract: Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R1, R1a, R1b, R2, R3, R4, X1, X2 and X3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.Type: ApplicationFiled: October 22, 2004Publication date: September 1, 2005Applicant: Neurocrine Biosciences, Inc.Inventors: Joe Tran, Fabio Tucci, Wanlong Jiang, Wei-Chuan Chen, Dragan Marinkovic, Melissa Arellano, Nicole White, Chen Chen
-
Publication number: 20050119252Abstract: Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R1, R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, X1, X2, X3, X4 and Ar are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.Type: ApplicationFiled: October 22, 2004Publication date: June 2, 2005Applicant: Neurocrine Biosciences, Inc.Inventors: Fabio Tucci, Joe Tran, Wei-Chuan Chen, Wanlong Jiang, Chen Chen
-
Publication number: 20050038057Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: ApplicationFiled: July 6, 2004Publication date: February 17, 2005Applicant: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley Dwight, Charles Huang, Fabio Tucci
-
Publication number: 20040162290Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women.Type: ApplicationFiled: November 10, 2003Publication date: August 19, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Dongpei Wu, Chen Chen, Fabio Tucci, Collin Regan
-
Patent number: 6677340Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1, R2, R3a, R3b, R4, R5, and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: August 2, 2002Date of Patent: January 13, 2004Assignee: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Dongpei Wu, Chen Chen, Fabio Tucci, Collin Regan
-
Publication number: 20030130282Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women.Type: ApplicationFiled: August 2, 2002Publication date: July 10, 2003Applicant: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Dongpei Wu, Chen Chen, Fabio Tucci, Collin Regan